Editas Medicine, Inc.
EDIT
Key stats
- Open
- 2.33
- Day high
- 2.33
- Day low
- 2.12
- Previous close
- 2.38
- Volume
- 3.89M
- VWAP
- 2.19
- 52-week high
- 3.94
- 52-week low
- 1.66
- Market cap
- 367.33M
- Shares out
- 153.58M
- Employees
- 87
- Listed
- 2016
About Editas Medicine, Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CAMBRIDGE, MA · editasmedicine.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 2.9K
- Put open interest
- 679
- Put/call
- 0.24
- At-the-money IV
- 259.9%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 1.50 call | 1.25 | Oct 28, 12:12 PM | 100 | 88 | 332.3% |
| 2.50 call | 0.05 | Nov 12, 3:41 PM | 30 | 2.7K | 138.4% |
| 1.50 put | 0.06 | Oct 13, 2:54 PM | 30 | 31 | 319.5% |
| 2 call | 0.57 | Nov 11, 2:44 PM | 6 | 13 | 259.9% |
| 1 call | 2.05 | Aug 6, 10:41 AM | 2 | 28 | 659.5% |
| 1 put | 0.05 | Oct 21, 2:09 PM | 1 | 11 | — |
Quarterly results
Massive · Nov 9, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $10.37M | $11.89M | $2.83M | $24.74M |
| Gross profit | $10.37M | $11.89M | $2.83M | $24.74M |
| Operating income | −$24.28M | −$18.55M | −$25.00M | −$7.75M |
| Net income | −$23.39M | −$18.23M | −$24.98M | −$5.62M |
| Diluted EPS | -0.15 | -0.15 | -0.26 | -0.06 |
| Operating cash flow | −$21.19M | −$29.57M | −$23.06M | −$36.39M |
| Assets | $219.41M | $237.36M | $149.34M | $186.53M |
| Liabilities | $134.89M | $132.08M | $144.93M | $159.25M |
| Equity | $84.52M | $105.28M | $4.41M | $27.29M |
Technicals
Massive · Nov 12, 2026- 50-day average2.65
- 200-day average2.70
- RSI (14 days)37.6
Short interest
Massive · Oct 30, 2026- Oct 30, 202638.72M shares · 17.6 days to cover
- Oct 15, 202638.19M shares · 14.3 days to cover
- Sep 30, 202637.11M shares · 9.3 days to cover
- Sep 15, 202629.96M shares · 15.7 days to cover
Related companies
MassiveNews coverage
No stories about Editas Medicine, Inc. right now.